Published in Gastroenterology on September 01, 1985
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med (1996) 3.47
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum. Gut (1989) 2.44
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet (1981) 2.02
Bacteria as the cause of ulcerative colitis. Gut (2001) 1.96
Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology (1998) 1.73
Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol (1994) 1.69
Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) Int J Epidemiol (1996) 1.65
Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol (1999) 1.62
Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol (2008) 1.61
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther (1994) 1.59
Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int (2001) 1.51
Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 1.49
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis (2007) 1.43
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol (2001) 1.43
Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther (2002) 1.41
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
Multiple radiculopathy of the lower limbs in a cancer patient with meningeal carcinomatosis. Neurol Sci (2000) 1.38
A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology (1986) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr (2000) 1.27
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol (1999) 1.23
Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol (1996) 1.21
[Epidemiological study on intestinal inflammatory diseases in the Province of Bologna]. G Clin Med (1977) 1.21
Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol (2001) 1.17
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology (1999) 1.16
Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol (1999) 1.16
New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol (2000) 1.16
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut (1985) 1.15
Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol (2002) 1.15
Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastroenterol Hepatol (1995) 1.12
Prostaglandins, indomethacin, and ulcerative colitis. Gastroenterology (1980) 1.11
The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest (1999) 1.09
Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum (2005) 1.09
Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther (2011) 1.07
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther (2002) 1.07
Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci (1994) 1.05
Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol (2003) 1.04
Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther (2002) 1.04
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther (2009) 1.03
Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol (1998) 1.03
Rectal cell proliferation and colon cancer risk in ulcerative colitis. Cancer Res (1990) 1.02
Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol (1992) 1.01
Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther (2005) 1.00
Epidemiological characteristics of inflammatory bowel disease in Bologna, Italy--incidence and risk factors. Digestion (1993) 1.00
Different patterns of intestinal transit time and anorectal motility in painful and painless chronic constipation. Gut (1984) 0.98
p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet (1994) 0.98
Clinical course of ulcerative colitis in Italy. Digestion (1980) 0.97